Transplant
Mouse and non-human primate studies suggest inhibiting CD122 could enhance the efficacy of Nulojix belatacept to treat GvHD, skin graft rejection and renal transplant rejection. In a mouse model of acute GvHD, the selective T cell co-stimulation inhibitor Nulojix plus an anti-CD122 mAb decreased proliferation of CD8+ and CD4+ T cells compared with Nulojix alone. In a mouse model of acute skin graft rejection, Nulojix plus the anti-CD122 mAb increased survival compared with either agent alone. In a non-human primate model of renal transplant rejection, the combination therapy increased survival. Next steps could include testing Nulojix plus CD122 inhibition in additional models of transplant rejection...
BCIQ Company Profiles
BCIQ Target Profiles